DK1107737T3 - Mikropartikler til anvendelse ved nålelös injektion - Google Patents

Mikropartikler til anvendelse ved nålelös injektion

Info

Publication number
DK1107737T3
DK1107737T3 DK99943130T DK99943130T DK1107737T3 DK 1107737 T3 DK1107737 T3 DK 1107737T3 DK 99943130 T DK99943130 T DK 99943130T DK 99943130 T DK99943130 T DK 99943130T DK 1107737 T3 DK1107737 T3 DK 1107737T3
Authority
DK
Denmark
Prior art keywords
microparticles
needless injection
therapeutic agent
needless
agent
Prior art date
Application number
DK99943130T
Other languages
English (en)
Inventor
Nicholas David Osborne
Original Assignee
Quadrant Drug Delivery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10838317&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1107737(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Quadrant Drug Delivery Ltd filed Critical Quadrant Drug Delivery Ltd
Application granted granted Critical
Publication of DK1107737T3 publication Critical patent/DK1107737T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Disintegrating Or Milling (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Glanulating (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK99943130T 1998-09-03 1999-09-03 Mikropartikler til anvendelse ved nålelös injektion DK1107737T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9819272.7A GB9819272D0 (en) 1998-09-03 1998-09-03 Microparticles

Publications (1)

Publication Number Publication Date
DK1107737T3 true DK1107737T3 (da) 2004-08-02

Family

ID=10838317

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99943130T DK1107737T3 (da) 1998-09-03 1999-09-03 Mikropartikler til anvendelse ved nålelös injektion

Country Status (15)

Country Link
US (3) US20020197325A1 (da)
EP (2) EP1410792B1 (da)
JP (2) JP2002524411A (da)
CN (1) CN1315854A (da)
AT (2) ATE386507T1 (da)
AU (1) AU5640799A (da)
BR (1) BR9913456A (da)
CA (1) CA2342206C (da)
DE (2) DE69938201T2 (da)
DK (1) DK1107737T3 (da)
ES (2) ES2301929T3 (da)
GB (1) GB9819272D0 (da)
IL (1) IL141323A0 (da)
MX (1) MXPA01002323A (da)
WO (1) WO2000013668A1 (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002538195A (ja) * 1999-03-08 2002-11-12 パウダージェクト リサーチ リミテッド 生物活性化合物の持続放出用の無針注射器を使用する微粒子製剤の送達
US8771740B2 (en) * 1999-12-20 2014-07-08 Nicholas J. Kerkhof Process for producing nanoparticles by spray drying
DE10045521A1 (de) 2000-03-31 2001-10-04 Roche Diagnostics Gmbh Nukleinsäureamplifikationen
US7575761B2 (en) 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
US20030152637A1 (en) * 2001-01-25 2003-08-14 Mark Chasin Local anesthetic, and method of use
EP1399132A1 (en) * 2001-06-08 2004-03-24 Powderject Vaccines, Inc. Production of hard, dense particles
EP1992335A1 (en) 2001-11-01 2008-11-19 Nektar Therapeutics Spray drying methods and compositions thereof
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
WO2005009375A2 (en) * 2003-07-22 2005-02-03 Baxter International Inc. Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof
JP4210231B2 (ja) * 2004-03-25 2009-01-14 株式会社資生堂 皮膚のシワを改善する美容方法及びシワ改善具
US8728525B2 (en) 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
EP1863451A2 (en) * 2005-03-31 2007-12-12 Rafael-Armament Development Authority Ltd. Spherically shaped substances
EP1912730A2 (en) * 2005-07-28 2008-04-23 Isp Investments Inc. Method to improve characteristics of spray dried powders and granulated materials, and the products thereby produced
EP1976486A1 (en) * 2006-01-27 2008-10-08 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin A method of producing porous microparticles
AU2007281737B2 (en) 2006-08-04 2013-09-19 Baxter Healthcare S.A. Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
DE202006018609U1 (de) * 2006-08-29 2007-05-16 Euro-Celtique S.A. Verwendung von Opioidformulierungen in nadellosen Vorrichtungen zur Medikamentenverabreichung
US20080085315A1 (en) * 2006-10-10 2008-04-10 John Alfred Doney Amorphous ezetimibe and the production thereof
WO2008076780A2 (en) * 2006-12-14 2008-06-26 Isp Investments Inc. Amorphous valsartan and the production thereof
WO2008080037A2 (en) * 2006-12-21 2008-07-03 Isp Investments Inc. Carotenoids of enhanced bioavailability
JP5508859B2 (ja) * 2007-01-26 2014-06-04 アイエスピー インヴェストメンツ インコーポレイテッド 噴霧乾燥製品を製造するための調剤処理方法
ITMI20080807A1 (it) 2008-05-05 2009-11-06 Antibioticos Spa Procedimento per la preparazione di tigeciclina in forma amorfa
US8323685B2 (en) 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing compositions containing microparticles
US8323615B2 (en) 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing multi-phasic dispersions
US8367427B2 (en) 2008-08-20 2013-02-05 Baxter International Inc. Methods of processing compositions containing microparticles
CN101732259B (zh) * 2009-12-29 2012-08-29 广东药学院 壳聚糖微米粒及其制备方法和应用
US9135998B2 (en) * 2010-11-09 2015-09-15 Micron Technology, Inc. Sense operation flags in a memory device
EP2898894A1 (en) 2014-01-27 2015-07-29 LTS LOHMANN Therapie-Systeme AG Nano-in-micro particles for intradermal delivery
US20200353127A1 (en) * 2018-01-10 2020-11-12 G2Gbio, Inc. Collagen peptide-containing polycaprolactone microsphere filler and preparation method therefor

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3937668A (en) * 1970-07-15 1976-02-10 Ilse Zolle Method for incorporating substances into protein microspheres
CA1077842A (en) * 1975-10-09 1980-05-20 Minnesota Mining And Manufacturing Company Albumin medicament carrier system
US4247406A (en) * 1979-04-23 1981-01-27 Widder Kenneth J Intravascularly-administrable, magnetically-localizable biodegradable carrier
US4349530A (en) * 1980-12-11 1982-09-14 The Ohio State University Implants, microbeads, microcapsules, preparation thereof and method of administering a biologically-active substance to an animal
US4357254A (en) * 1981-01-12 1982-11-02 Chemical Sciences, Inc. Cleaning composition
FR2505657A1 (fr) * 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
US5707644A (en) * 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
FR2663224B1 (fr) * 1990-06-14 1995-01-20 Applicationes Farmaceuticas Sa Forme galenique parenterale.
AU669952B2 (en) * 1992-10-16 1996-06-27 Glaxo Group Limited Taste-masking compositions of ranitidine
TW404844B (en) * 1993-04-08 2000-09-11 Oxford Biosciences Ltd Needleless syringe
US5899880A (en) * 1994-04-08 1999-05-04 Powderject Research Limited Needleless syringe using supersonic gas flow for particle delivery
NZ288185A (en) * 1994-06-15 1998-02-26 Dumex Alpharma As Particulate pharmaceutical formulation containing coated cores comprising at least 80% of an inert carrier having a friability of <20%; the inert carrier can be calcium carbonate
IT1274879B (it) * 1994-08-03 1997-07-25 Saitec Srl Apparecchio e metodo per preparare forme farmaceutiche solide a rilascio controllato del principio attivo.
GB9502879D0 (en) * 1995-02-14 1995-04-05 Oxford Biosciences Ltd Particle delivery
KR100201352B1 (ko) * 1995-03-16 1999-06-15 성재갑 단일주사 백신 제형
US5922253A (en) * 1995-05-18 1999-07-13 Alkermes Controlled Therapeutics, Inc. Production scale method of forming microparticles
US6117449A (en) * 1996-03-22 2000-09-12 Bio-Sphere Technology, Inc. Method for inducing a systemic immune response to a hepatitis antigen
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
GB9612629D0 (en) * 1996-06-17 1996-08-21 Oxford Biosciences Ltd Method for providing dense particle compositions for use in transdermal particle delivery

Also Published As

Publication number Publication date
DE69938201D1 (de) 2008-04-03
WO2000013668A1 (en) 2000-03-16
EP1107737A1 (en) 2001-06-20
JP2002524411A (ja) 2002-08-06
CA2342206C (en) 2006-12-12
US20070026081A1 (en) 2007-02-01
ATE386507T1 (de) 2008-03-15
IL141323A0 (en) 2002-03-10
US20020197325A1 (en) 2002-12-26
BR9913456A (pt) 2001-07-24
EP1410792A1 (en) 2004-04-21
MXPA01002323A (es) 2002-05-08
EP1410792A8 (en) 2004-12-29
CA2342206A1 (en) 2000-03-16
US20050002870A1 (en) 2005-01-06
JP2006096755A (ja) 2006-04-13
AU5640799A (en) 2000-03-27
EP1410792B1 (en) 2008-02-20
EP1107737B1 (en) 2004-04-28
ES2301929T3 (es) 2008-07-01
GB9819272D0 (en) 1998-10-28
DE69916856T2 (de) 2005-04-21
ATE265204T1 (de) 2004-05-15
CN1315854A (zh) 2001-10-03
ES2223181T3 (es) 2005-02-16
DE69938201T2 (de) 2009-02-12
DE69916856D1 (de) 2004-06-03

Similar Documents

Publication Publication Date Title
DE69916856T2 (de) Micropartikeln zur verwendung in nadellosen injektion
WO1999014346A3 (en) SENSE mRNA THERAPY
HU913776D0 (en) Process for the production of heparosane-n,o-sulphates, and medical preparations containing them as active agents
NO20015584L (no) Langtidsvarende insulintropiske peptider og konjugater samt anvendelse for fremstilling av medikamenter for behandling
MX9603925A (es) Combinaciones de anticoagulantes y proteinas activas tromboliticamente, y usos de las mismas.
NO986089D0 (no) Metoder og preparater for behandling av tumorer, tumorrelaterte sykdommer o
NO961291L (no) Prosess II
ID30116A (id) Turunan-turunan piridopiranoazepin, pembuatannya dan penggunaan terapinya
IL164839A0 (en) Pharmaceutical agents for the treatment of parkinson&#39;s disease, adhd and microadenomas
EE9900477A (et) Ühendid ja kompositsioonid seriinproteaasse, eriti trüptaasse aktiivsusega seotud haiguste raviks
IT1290781B1 (it) Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.
ATE271852T1 (de) Verbesserte inhalationspräparate
BG105204A (en) Salts of paroxetine
HU913267D0 (en) Process for the production of 1-(3,4-dihydro-2-oxo-1h-kinoline-6-yl)-2-(4-)2-phenyl-ethyl-(piperidine-1-yl)-ethanole and ethanone, and of medical preparations containing them as active agents
BG66081B1 (bg) Състави, съдържащи модафинилни съединения
GB2395903B (en) Dickkopf 5 gene, protein and antibodies: a role in the treatment and diagnosis of insulin-resistant states
IL148980A0 (en) An antibody to human tissue factor and experimental animals having inserted cells with the gene encoding human tissue factor
IT1285158B1 (it) Polipeptidi solubili con l&#39;attivita&#39; di serino-proteasi di ns3 del virus dell&#39;epatite c, e procedimento per la loro preparazione e il
PL345710A1 (en) 2,5-substituted benzolsulfonylureas and thioureas, methods for the production thereof, use thereof and pharmaceutical preparations containing the same
ES8505968A1 (es) Procedimiento para preparar (6-(etil-(2-hidroxipropil)-amino)-3-piridazinil)-hidrazinocarboxilato de etilo
DE60010230D1 (de) Pharmazeutische zusammensetzung von hydrophob modifizierten hedgehog-proteinen und deren verwendung
RU2000112951A (ru) Способ лечения гифемы
Liao et al. Analysis and Numerical Simulation of the Cross Equatorial Flow of 1991
GB0012974D0 (en) Method for producing of 2,3-dimethylbutene-1 and 2,3-dimethylbutene-2
RU99107944A (ru) Лечебное средство прямого антикоагулянтного и фибринолитического действия